Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions

Last updated: September 24, 2018
Sponsor: Ain Shams University
Overall Status: Active - Recruiting

Phase

4

Condition

Oral Cancer

Treatment

N/A

Clinical Study ID

NCT03684707
Cairo University
  • Ages 20-60
  • All Genders

Study Summary

Evaluation of the metformin drug effect as a drug that found to improve the quality of tissues, decrease signs & symptoms of cancer, and decrease histo-pathological criteria of dysplasia.

This will be done by the aid of measuring salivary Micro RNA 31 & 210 in saliva in addition to measure cyclin A2 as an immuno-histochemical analysis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Both genders with age range from 20 to 70 years.

  • Patients able to return for the follow up visits and can perform oral hygienemeasures.

  • Clinically diagnosed and histologically confirmed as having oral potentially malignantlesions.

  • Patients agreed to sign a written consent after understanding the nature of the study

  • Patients have diagnosed oral premalignant lesion/lesions and not yet turned intomalignancy (atrophic lichen planus- leukoplakia-erythroplakia - oral submucousfibrosis)

Exclusion

Exclusion Criteria:

    • Diabetic patients (Diabetes Mellitus Type I & II)

  • Patients have cardiovascular, lung, Renal, Liver diseases

  • Patients on H2 blocker & proton pump inhibitors therapy as Ranitidine (affectsmetformin absorption and clearance)

  • Those with allergy or sensitivity to Metformin or Retinoids therapy or having anycontraindication for their use.

  • Systemic and/or local systemic drug therapy within the last 3 months prior to thestart of the study

  • Patients on steroidal or Non-steroidal anti-inflammatory drugs (NSAIDs) for at leastthe last 6 months

  • Patients on Antibiotics treatment for at least the last 2 months

  • Patients on Retinoid, green tea supplements or another natural products therapy

  • Patients with already diagnosed malignant lesion/lesions

  • Pregnant or Lactating females

  • Vulnerable groups as prisoners, mentally disabled, etc…

Study Design

Total Participants: 30
Study Start date:
September 15, 2018
Estimated Completion Date:
September 15, 2019

Study Description

Oral squamous cell carcinomas (OSCCs) are among the most common types of head and neck cancers and are a major cause of significant morbidity. It was reported that 16- 62% of OSCCs develop from premalignant lesions, which often presents clinically as white or red mucosal patches known as leukoplakia and erythroplakia. The role of miRNA in cancer has been reiterated and established by many studies that have shown that miRNA signatures (i.e., mRNA expression profiles) can be useful for classifying human cancers. These studies have identified "cancer related miRNAs" through investigating expression profiles in matched normal and tumor tissues, as well as in body fluids. In addition, a vast number of studies have shown that miRNAs can play a role in regulating the expression of oncogenes and tumor suppressor genes, whereas others have shown that miRNA gene deletion or mutation can lead cancer initiation, progression and metastasis . Several potential mechanisms have been suggested for the ability of metformin to suppress cancer growth in vitro and vivo:

(1) Activation of LKB1/AMPK pathway, (2) Induction of cell cycle arrest and/or apoptosis, (3) Inhibition of protein synthesis, (4) Reduction in circulating insulin levels, (5) Inhibition of the unfolded protein response (UPR), (6) Activation of the immune system.

This study is performed to evaluate metformin effect on the patients premalignant lesion versus maintenace follow ups.

Connect with a study center

  • Noha Nasr

    Cairo, New Cairo 11835
    Egypt

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.